Mesoblast (NASDAQ:MESO) Upgraded to “Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Mesoblast (NASDAQ:MESO) from a hold rating to a buy rating in a research report sent to investors on Thursday, Marketbeat reports.

Several other analysts have also issued reports on MESO. Chardan Capital dropped their target price on shares of Mesoblast from $2.00 to $1.50 and set a sell rating on the stock in a research report on Friday, August 4th. Piper Sandler lowered shares of Mesoblast from an overweight rating to a neutral rating and dropped their target price for the company from $7.00 to $2.00 in a research report on Friday, August 4th. Cantor Fitzgerald dropped their target price on shares of Mesoblast from $23.00 to $17.00 and set an overweight rating on the stock in a research report on Thursday. William Blair lowered shares of Mesoblast from an outperform rating to a market perform rating in a research report on Friday, August 4th. Finally, Maxim Group lowered shares of Mesoblast from a buy rating to a hold rating in a research report on Monday, August 7th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Hold and a consensus price target of $7.13.

Mesoblast Trading Up 12.6 %

Shares of Mesoblast stock opened at $1.61 on Thursday. Mesoblast has a 1 year low of $1.16 and a 1 year high of $5.12. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.14 and a quick ratio of 1.14. The firm has a fifty day moving average price of $3.06 and a 200 day moving average price of $3.31. The stock has a market cap of $262.17 million, a PE ratio of -2.73 and a beta of 3.21.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Wednesday, August 30th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Mesoblast had a negative net margin of 1,043.64% and a negative return on equity of 16.27%. The company had revenue of $2.14 million during the quarter, compared to analysts’ expectations of $2.00 million. Equities research analysts predict that Mesoblast will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On Mesoblast

A number of institutional investors have recently bought and sold shares of MESO. Tobias Financial Advisors Inc. purchased a new stake in shares of Mesoblast in the 4th quarter valued at approximately $58,000. Aries Wealth Management purchased a new stake in shares of Mesoblast in the 1st quarter valued at approximately $33,000. Vident Investment Advisory LLC raised its stake in shares of Mesoblast by 12.8% in the 4th quarter. Vident Investment Advisory LLC now owns 28,080 shares of the company’s stock valued at $82,000 after acquiring an additional 3,191 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Mesoblast by 99.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,008 shares of the company’s stock valued at $76,000 after acquiring an additional 12,954 shares during the period. Finally, EWA LLC purchased a new stake in shares of Mesoblast in the 1st quarter valued at approximately $40,000. 2.60% of the stock is owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.